Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 1/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL775468 | 0.88 | TAAR1 (0.55) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL3371633 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL22857553 | 0.83 | TAAR1 (0.59) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL19432539 | 0.83 | TAAR1 (0.59) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL30753694 | 0.80 | TP53 (0.56) | TAAR1IDO1AGXTDAOMIF | |
| SCHEMBL23014831 | 0.79 | TAAR1 (0.46) | TAAR1SLC6A3DRD2SLC6A4 | |
| SCHEMBL576677 | 0.79 | RAB9A (0.54) | TAAR1IDO1AGXTDAOMIF | |
| SCHEMBL29723380 | 0.79 | RAB9A (0.54) | TAAR1IDO1AGXTDAOMIF | |
| SCHEMBL144864 | 0.79 | TAAR1 (0.72) | TAAR1SLC6A3IDO1AGXTDAO | |
| SCHEMBL8591746 | 0.79 | TAAR1 (0.65) | TAAR1SLC6A3IDO1AGXTDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9590270-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9553334-B2 | — | — | 2017-01-24 | — | — | US | disclosed |
| US-9281541-B2 | Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | TAAR1 2844/4885SLC6A3 2998/4885IDO1 911/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | TAAR1 1531/4885SLC6A3 1305/4885IDO1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.